Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Guideline
. 2014 Jul;108(5):825-32.
doi: 10.1016/j.eplepsyres.2014.02.011. Epub 2014 Mar 1.

Inclusion and exclusion criteria for epilepsy clinical trials-recommendations from the April 30, 2011 NINDS workshop

Evan Fertig  1 , Brandy E Fureman  2 , Gregory K Bergey  3 , Mary Ann Brodie  4 , Dale C Hesdorffer  5 , Deborah Hirtz  6 , Eric H Kossoff  7 , W Curt LaFrance Jr  8 , Mark Versavel  9 , Jacqueline French  10 ; National Institute of Neurological Disorders and Stroke
Affiliations
Guideline

Inclusion and exclusion criteria for epilepsy clinical trials-recommendations from the April 30, 2011 NINDS workshop

Evan Fertig et al. Epilepsy Res. 2014 Jul.

Abstract

On April 30th, 2011 the National Institute of Neurological Disorders and Stroke (NINDS) held a workshop to identify key problems in recent epilepsy clinical trials and propose approaches to address the barriers that impede development of new therapeutic options for epilepsy. Preliminary recommendations were made for selection criteria for subjects entered into epilepsy trials that maximize the scientific impact of the trial and increase the ability to recruit appropriate subjects efficiently and safely. These recommendations were further refined by the authors following the workshop, and subsequently shared with all NINDS workshop participants and with the participants of the 2011 AED XI workshop on epilepsy trials (approximately 200 participants) for further comment. The working group agreed to a final set of criteria that include updated considerations of subject age, clinical semiology, EEG and imaging results, use of prior and current therapies, co-occurring conditions, and suicidality, among others.

Keywords: Clinical trial methodology; Comorbidity; Participant selection criteria; Recruitment.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Conflict of Interest

Evan Fertig is an employee of the Northeast Regional Epilepsy Group. He has received research support from Pfizer, UCB, Lundbeck, Vertex, Supernus, and Esai.

Brandy Fureman is an employee of the NINDS, NIH.

Gregory K. Bergey is an employee of the Johns Hopkins University School of Medicine.

Mary Ann Brodie is an employee of the Epilepsy Study Consortium. Within the past year, the Epilepsy Consortium has received funding for research support, meeting support and services provided from the following companies: Cyberonics, Eisai Medical Research, GlaxoSmithKline, Icagen, Inc., Johnson & Johnson, Marinus, Neurotherapeutics, NeuroVista Corporation, Ono Pharma USA, Inc., Lundbeck, Pfizer, Sepracor, Sunovion, SK Life Science, Supernus Pharmaceuticals, UCB Inc/Schwarz Pharma, Upsher Smith, Valeant, Vertex.

Dale C. Hesdorffer is an employee of GH Sergievsky Center and Department of Epidemiology, Columbia University. She has received travel funding from GlaxoSmithKline and the International League Against Epillepsy, and grant funding from the CDC, the NINDS, NICHD, the Epilepsy Study Consortium, and the Epilepsy Foundation of America.

Deborah Hirtz is an employee of the NINDS, NIH.

Eric H. Kossoff is an employee of the Johns Hopkins University School of Medicine.

W Curt LaFrance, Jr. is employed by Rhode Island Hospital. He has received grant support from NINDS, the American Epilepsy Society, the Epilepsy Foundation, Brown University and the Siravo Foundation. Dr. LaFrance receives book royalties for Gates and Rowan’s Nonepileptic Seizures, 3rd Edition, Cambridge University Press.

Mark Versavel is an employee of Sunovion Inc.

Jackie French serves as the president of The Epilepsy Study Consortium, a non-profit organization. NYU receives a fixed amount from the Epilepsy Study Consortium towards Dr. French’s salary. The money is for work performed by Dr. French on behalf of The Epilepsy Study Consortium, for consulting and clinical trial related activities. Dr French receives no personal income for these activities. Within the past year, The Epilepsy Study Consortium received payments from: Cyberonics, Eisai Medical Research, Entra Pharmaceuticals, GlaxoSmithKline, Icagen, Inc., Johnson & Johnson, Marinus, Neurotherapeutics, NeuroVista Corporation, Ono Pharma USA, Inc., Lundbeck, Pfizer, Sepracor, Sunovion, SK Life Science, Supernus Pharmaceuticals, UCB Inc./Schwarz Pharma, Upsher Smith, Valeant, Vertex.

References

    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5. American Psychiatric Publishing; Washington DC: 2013. DSM-5.
    1. [Accessed 9 September 2013];Declaration of Helsinki. 6th revision www.wma.net/en/30publications/10policies/b3/index.html.
    1. [Accessed 25 October 2013];Guidance for Industry: General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati....
    1. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French JA, Glauser TA, Mathern GW, Moshé SL, Nordli D, Plouin P, Scheffer IE. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia. 2010;51:676–85. - PubMed
    1. Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548–54. - PMC - PubMed

Publication types

MeSH terms

Substances